rat anti-mouse igg 2a (2a3 Search Results


anti cd25 pe  (Miltenyi Biotec)
96
Miltenyi Biotec anti cd25 pe
Anti Cd25 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd25 pe/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
anti cd25 pe - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
rat igg2a  (Bio X Cell)
96
Bio X Cell rat igg2a
Rat Igg2a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat igg2a/product/Bio X Cell
Average 96 stars, based on 1 article reviews
rat igg2a - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
igg control  (Bio X Cell)
98
Bio X Cell igg control
Igg Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg control/product/Bio X Cell
Average 98 stars, based on 1 article reviews
igg control - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
isotype control rat igg2b  (Bio X Cell)
98
Bio X Cell isotype control rat igg2b
Isotype Control Rat Igg2b, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/isotype control rat igg2b/product/Bio X Cell
Average 98 stars, based on 1 article reviews
isotype control rat igg2b - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
anti-cd25 [2a3]  (Becton Dickinson)
90
Becton Dickinson anti-cd25 [2a3]
Anti Cd25 [2a3], supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd25 [2a3]/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-cd25 [2a3] - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti pd 1  (Bio X Cell)
96
Bio X Cell anti pd 1
Anti Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pd 1/product/Bio X Cell
Average 96 stars, based on 1 article reviews
anti pd 1 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
anti-cd25 pecy7  (Becton Dickinson)
90
Becton Dickinson anti-cd25 pecy7
Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of peak VZV-specific Th1 immune responses to ZVL in the primary cohort ( n = 399) a
Anti Cd25 Pecy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd25 pecy7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-cd25 pecy7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti cd25  (fluidigm)
95
fluidigm anti cd25

Anti Cd25, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd25/product/fluidigm
Average 95 stars, based on 1 article reviews
anti cd25 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
bp0131 invivomab rat igg2a isotype control  (Bio X Cell)
98
Bio X Cell bp0131 invivomab rat igg2a isotype control

Bp0131 Invivomab Rat Igg2a Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bp0131 invivomab rat igg2a isotype control/product/Bio X Cell
Average 98 stars, based on 1 article reviews
bp0131 invivomab rat igg2a isotype control - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
anti trinitrophenol bio x cell  (Bio X Cell)
98
Bio X Cell anti trinitrophenol bio x cell

Anti Trinitrophenol Bio X Cell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti trinitrophenol bio x cell/product/Bio X Cell
Average 98 stars, based on 1 article reviews
anti trinitrophenol bio x cell - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
anti-cd25-pe-cy7 (2a3  (Thermo Fisher)
90
Thermo Fisher anti-cd25-pe-cy7 (2a3
a. PBMCs gating strategy: <t>CD25+Foxp3+</t> (nTreg), CD25-Foxp3+ (Th3 cells), and CTLA-4+CD25− (Tr1 cells) cells were selected within the CD4+ cell population. b. Correlation of absolute numbers of CD4+CD25+CD127− and CD4+CD25+Foxp3+ cells. c. An absolute number of nTreg in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). *, p< 0.05; ***, p< 0.001. d. An absolute number of Th3 cells in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). ***, p< 0.001. e. An absolute number of Tr1 cells in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). f. An absolute number of nTreg, Th3 cells, or Tr1 cells in peripheral blood of controls and patients with MF/SzS according to T stage. g. nTreg gating strategy in SzS patients: within the tumor subset that is TCR Vβ2 positive (TS) and the non-tumor cell subset that is TCR Vβ2 negative (NTS) (a representative patient). h. An absolute number of CD4+CD25+Foxp3+ cells in peripheral blood of controls and patients with SzS within a tumor subset (T-SzS) and a non-tumor subset (NT-SzS). *, p<0.05, ***, p< 0.001. i. Isolated CD4+CD25+ cells suppress proliferation of CFSE-labeled autologous CD4+CD25− T cells in proliferation assays. A representative experiment (6 performed). j. CD4+CD25+ lymphocytes from patients demonstrate significantly higher suppressive activity than normal controls. ***, p < 0.001
Anti Cd25 Pe Cy7 (2a3, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd25-pe-cy7 (2a3/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-cd25-pe-cy7 (2a3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of peak VZV-specific Th1 immune responses to ZVL in the primary cohort ( n = 399) a

Journal: Journal of Virology

Article Title: The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity

doi: 10.1128/JVI.00305-19

Figure Lengend Snippet: Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of peak VZV-specific Th1 immune responses to ZVL in the primary cohort ( n = 399) a

Article Snippet: Cells were stained with viability dye (catalog number 423104; BioLegend) and then surface stained with anti-ICOS Ax488 (Alexa Fluor 488) (clone C398.4A, catalog number 313514; BioLegend), anti-CTLA4 PE-CF594 (cyanine-based fluorescent 594) (clone BNI3, catalog number 562742; BD), anti-LAG3 PerCP-Cy5.5 (clone 11C3C65, catalog number 369312; BioLegend), anti-CD25 PECy7 (clone 2A3, catalog number 335807; BD), anti-CD39 APC (clone TU66, catalog number 560239; BD), anti-CD4 Ax700 (clone RPA-T4, catalog number 557922; BD), anti-CD3 APC-H7 (clone SK7, catalog number 560176; BD), and anti-CD127 BV421 (clone A019D5, catalog number 351310; BioLegend).

Techniques:

Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of peak VZV-specific CTL and Tfh responses to ZVL in the VZV-specific flow cytometry subset of the primary cohort ( n = 95) a

Journal: Journal of Virology

Article Title: The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity

doi: 10.1128/JVI.00305-19

Figure Lengend Snippet: Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of peak VZV-specific CTL and Tfh responses to ZVL in the VZV-specific flow cytometry subset of the primary cohort ( n = 95) a

Article Snippet: Cells were stained with viability dye (catalog number 423104; BioLegend) and then surface stained with anti-ICOS Ax488 (Alexa Fluor 488) (clone C398.4A, catalog number 313514; BioLegend), anti-CTLA4 PE-CF594 (cyanine-based fluorescent 594) (clone BNI3, catalog number 562742; BD), anti-LAG3 PerCP-Cy5.5 (clone 11C3C65, catalog number 369312; BioLegend), anti-CD25 PECy7 (clone 2A3, catalog number 335807; BD), anti-CD39 APC (clone TU66, catalog number 560239; BD), anti-CD4 Ax700 (clone RPA-T4, catalog number 557922; BD), anti-CD3 APC-H7 (clone SK7, catalog number 560176; BD), and anti-CD127 BV421 (clone A019D5, catalog number 351310; BioLegend).

Techniques: Flow Cytometry

Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of persistent VZV-specific Th1 cells 1 year after ZVL administration in the primary cohort ( n = 399) a

Journal: Journal of Virology

Article Title: The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity

doi: 10.1128/JVI.00305-19

Figure Lengend Snippet: Multivariable regression analysis of the effects of age and baseline immune parameters on the magnitude of persistent VZV-specific Th1 cells 1 year after ZVL administration in the primary cohort ( n = 399) a

Article Snippet: Cells were stained with viability dye (catalog number 423104; BioLegend) and then surface stained with anti-ICOS Ax488 (Alexa Fluor 488) (clone C398.4A, catalog number 313514; BioLegend), anti-CTLA4 PE-CF594 (cyanine-based fluorescent 594) (clone BNI3, catalog number 562742; BD), anti-LAG3 PerCP-Cy5.5 (clone 11C3C65, catalog number 369312; BioLegend), anti-CD25 PECy7 (clone 2A3, catalog number 335807; BD), anti-CD39 APC (clone TU66, catalog number 560239; BD), anti-CD4 Ax700 (clone RPA-T4, catalog number 557922; BD), anti-CD3 APC-H7 (clone SK7, catalog number 560176; BD), and anti-CD127 BV421 (clone A019D5, catalog number 351310; BioLegend).

Techniques:

Multivariable regression analysis of the effects of age and baseline and peak immune parameters on the magnitude of persistent VZV-specific Th1 cells 1 year after ZVL administration in the primary cohort ( n = 399) a

Journal: Journal of Virology

Article Title: The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity

doi: 10.1128/JVI.00305-19

Figure Lengend Snippet: Multivariable regression analysis of the effects of age and baseline and peak immune parameters on the magnitude of persistent VZV-specific Th1 cells 1 year after ZVL administration in the primary cohort ( n = 399) a

Article Snippet: Cells were stained with viability dye (catalog number 423104; BioLegend) and then surface stained with anti-ICOS Ax488 (Alexa Fluor 488) (clone C398.4A, catalog number 313514; BioLegend), anti-CTLA4 PE-CF594 (cyanine-based fluorescent 594) (clone BNI3, catalog number 562742; BD), anti-LAG3 PerCP-Cy5.5 (clone 11C3C65, catalog number 369312; BioLegend), anti-CD25 PECy7 (clone 2A3, catalog number 335807; BD), anti-CD39 APC (clone TU66, catalog number 560239; BD), anti-CD4 Ax700 (clone RPA-T4, catalog number 557922; BD), anti-CD3 APC-H7 (clone SK7, catalog number 560176; BD), and anti-CD127 BV421 (clone A019D5, catalog number 351310; BioLegend).

Techniques:

Expression of FOXP3 and inhibitory ligands on CD4+ CD25+ CD127− Treg. Data were derived from 6 adults of all ages. The parent population is indicated on the abscissa. Horizontal bars indicate paired comparisons and P values.

Journal: Journal of Virology

Article Title: The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity

doi: 10.1128/JVI.00305-19

Figure Lengend Snippet: Expression of FOXP3 and inhibitory ligands on CD4+ CD25+ CD127− Treg. Data were derived from 6 adults of all ages. The parent population is indicated on the abscissa. Horizontal bars indicate paired comparisons and P values.

Article Snippet: Cells were stained with viability dye (catalog number 423104; BioLegend) and then surface stained with anti-ICOS Ax488 (Alexa Fluor 488) (clone C398.4A, catalog number 313514; BioLegend), anti-CTLA4 PE-CF594 (cyanine-based fluorescent 594) (clone BNI3, catalog number 562742; BD), anti-LAG3 PerCP-Cy5.5 (clone 11C3C65, catalog number 369312; BioLegend), anti-CD25 PECy7 (clone 2A3, catalog number 335807; BD), anti-CD39 APC (clone TU66, catalog number 560239; BD), anti-CD4 Ax700 (clone RPA-T4, catalog number 557922; BD), anti-CD3 APC-H7 (clone SK7, catalog number 560176; BD), and anti-CD127 BV421 (clone A019D5, catalog number 351310; BioLegend).

Techniques: Expressing, Derivative Assay

Journal: iScience

Article Title: Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling

doi: 10.1016/j.isci.2024.110837

Figure Lengend Snippet:

Article Snippet: Anti-CD25 (clone 2A3, conjugated to 149Sm) , Standard BioTools , Cat#3149010B.

Techniques: Purification, Clinical Proteomics, Recombinant, Blocking Assay, Staining, Saline, Mass Cytometry, Software, Cytometry

a. PBMCs gating strategy: CD25+Foxp3+ (nTreg), CD25-Foxp3+ (Th3 cells), and CTLA-4+CD25− (Tr1 cells) cells were selected within the CD4+ cell population. b. Correlation of absolute numbers of CD4+CD25+CD127− and CD4+CD25+Foxp3+ cells. c. An absolute number of nTreg in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). *, p< 0.05; ***, p< 0.001. d. An absolute number of Th3 cells in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). ***, p< 0.001. e. An absolute number of Tr1 cells in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). f. An absolute number of nTreg, Th3 cells, or Tr1 cells in peripheral blood of controls and patients with MF/SzS according to T stage. g. nTreg gating strategy in SzS patients: within the tumor subset that is TCR Vβ2 positive (TS) and the non-tumor cell subset that is TCR Vβ2 negative (NTS) (a representative patient). h. An absolute number of CD4+CD25+Foxp3+ cells in peripheral blood of controls and patients with SzS within a tumor subset (T-SzS) and a non-tumor subset (NT-SzS). *, p<0.05, ***, p< 0.001. i. Isolated CD4+CD25+ cells suppress proliferation of CFSE-labeled autologous CD4+CD25− T cells in proliferation assays. A representative experiment (6 performed). j. CD4+CD25+ lymphocytes from patients demonstrate significantly higher suppressive activity than normal controls. ***, p < 0.001

Journal: Cancer immunology, immunotherapy : CII

Article Title: Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome

doi: 10.1007/s00262-017-2090-z

Figure Lengend Snippet: a. PBMCs gating strategy: CD25+Foxp3+ (nTreg), CD25-Foxp3+ (Th3 cells), and CTLA-4+CD25− (Tr1 cells) cells were selected within the CD4+ cell population. b. Correlation of absolute numbers of CD4+CD25+CD127− and CD4+CD25+Foxp3+ cells. c. An absolute number of nTreg in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). *, p< 0.05; ***, p< 0.001. d. An absolute number of Th3 cells in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). ***, p< 0.001. e. An absolute number of Tr1 cells in peripheral blood of controls and patients with IA MF, >IB MF, or SzS (M±SEM). f. An absolute number of nTreg, Th3 cells, or Tr1 cells in peripheral blood of controls and patients with MF/SzS according to T stage. g. nTreg gating strategy in SzS patients: within the tumor subset that is TCR Vβ2 positive (TS) and the non-tumor cell subset that is TCR Vβ2 negative (NTS) (a representative patient). h. An absolute number of CD4+CD25+Foxp3+ cells in peripheral blood of controls and patients with SzS within a tumor subset (T-SzS) and a non-tumor subset (NT-SzS). *, p<0.05, ***, p< 0.001. i. Isolated CD4+CD25+ cells suppress proliferation of CFSE-labeled autologous CD4+CD25− T cells in proliferation assays. A representative experiment (6 performed). j. CD4+CD25+ lymphocytes from patients demonstrate significantly higher suppressive activity than normal controls. ***, p < 0.001

Article Snippet: Cell staining was performed with anti-CD4-APC (RPA-T4) from BD Pharmingen (San Diego, CA), anti-CD25-PE-Cy7 (2A3) from Caltag Laboratories (Burlingame, CA), anti-Foxp3-FITC (236A/E7) from eBioscence (San Diego, CA) and anti-CD127-PE (HIL-7R-M21) from BD Pharmingen (San Diego, CA).

Techniques: Isolation, Labeling, Activity Assay

a. 59-year-old male with SzS stage IVA1 (T4N0M0B2) at diagnosis. b. 89% of clonal Vβ23 positive CD4 cells express CD25+Foxp3+. c. Malignant cells with nTreg phenotype exhibit cell-cell suppression activity (incubation at 1:1 ratio for 5 days).

Journal: Cancer immunology, immunotherapy : CII

Article Title: Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome

doi: 10.1007/s00262-017-2090-z

Figure Lengend Snippet: a. 59-year-old male with SzS stage IVA1 (T4N0M0B2) at diagnosis. b. 89% of clonal Vβ23 positive CD4 cells express CD25+Foxp3+. c. Malignant cells with nTreg phenotype exhibit cell-cell suppression activity (incubation at 1:1 ratio for 5 days).

Article Snippet: Cell staining was performed with anti-CD4-APC (RPA-T4) from BD Pharmingen (San Diego, CA), anti-CD25-PE-Cy7 (2A3) from Caltag Laboratories (Burlingame, CA), anti-Foxp3-FITC (236A/E7) from eBioscence (San Diego, CA) and anti-CD127-PE (HIL-7R-M21) from BD Pharmingen (San Diego, CA).

Techniques: Activity Assay, Incubation

a. The percentage of Treg in the peripheral blood among CD4+ cells of a representative patient before and after a 5-day course of DD. b. The absolute number of Treg in the peripheral blood of patients before and after DD (9 patients; 12 different before and after cycles) in responders and non-responders (percent from baseline). c. Treg in the skin of MF/SzS patients before and after the first cycle of DD. Skin samples were evaluated for co-expression of CD4 and Foxp3 by fluorescence microscopy. Left: before therapy; Right: after therapy. Nuclei stained with Hoechst dye (blue). 10x d. Variation in the percentage of CD4+CD25+Foxp3+ cells during extended DD therapy (patient 3). e. Variation in the percentage of CD4+CD25+Foxp3+ cells during extended DD therapy (patient 5). f. The percentage of MDSC before and after a 5-day course of DD. Results from a representative patient are shown. g. The absolute number of MDSC in peripheral blood of patients before and after a 5-day course of DD in 5 patients.

Journal: Cancer immunology, immunotherapy : CII

Article Title: Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome

doi: 10.1007/s00262-017-2090-z

Figure Lengend Snippet: a. The percentage of Treg in the peripheral blood among CD4+ cells of a representative patient before and after a 5-day course of DD. b. The absolute number of Treg in the peripheral blood of patients before and after DD (9 patients; 12 different before and after cycles) in responders and non-responders (percent from baseline). c. Treg in the skin of MF/SzS patients before and after the first cycle of DD. Skin samples were evaluated for co-expression of CD4 and Foxp3 by fluorescence microscopy. Left: before therapy; Right: after therapy. Nuclei stained with Hoechst dye (blue). 10x d. Variation in the percentage of CD4+CD25+Foxp3+ cells during extended DD therapy (patient 3). e. Variation in the percentage of CD4+CD25+Foxp3+ cells during extended DD therapy (patient 5). f. The percentage of MDSC before and after a 5-day course of DD. Results from a representative patient are shown. g. The absolute number of MDSC in peripheral blood of patients before and after a 5-day course of DD in 5 patients.

Article Snippet: Cell staining was performed with anti-CD4-APC (RPA-T4) from BD Pharmingen (San Diego, CA), anti-CD25-PE-Cy7 (2A3) from Caltag Laboratories (Burlingame, CA), anti-Foxp3-FITC (236A/E7) from eBioscence (San Diego, CA) and anti-CD127-PE (HIL-7R-M21) from BD Pharmingen (San Diego, CA).

Techniques: Expressing, Fluorescence, Microscopy, Staining